Two Independent Peer-Reviewed Studies Validate Cernostics’ TissueCypher® Barrett’s Esophagus Assay (TissueCypher®) to Accurately Predict Progression to Esophageal Cancer in Patients with Barrett’s Esophagus Pittsburgh, PA, Nov. 18, 2020 (GLOBE NEWSWIRE) -- Cernostics, Inc. the GI Precision Medicine company, today announced two newly completed clinical studies confirming the ability of the TissueCypher®...